

**TABLE 87: COMBINED TREATMENT EXPERIENCE**

INCLUDED STUDIES	POPULATION	ITT, N	TREATMENT ARM	AGE (YEARS) MEAN (SD)/MEDIAN (RANGE)	% MALE	PREVIOUS TREATMENT EXPERIENCE				PREVIOUS RESPONSE			GENOTYPE AND SUBTYPE (%)								PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)			
						PR (%)	DAA + PR (%)	DAA ONLY (%)	MIXED	RELAPSE (%)	NULL (%)	PARTIAL (%)	1	1a	1b	2	3	4	5	6	COMBINED/ OTHER	CIRRHOTIC (%)		NON-CIRRHOTIC (%)		
<b>Studies included in the NMA</b>																										
Dieterich et al., 2014	Naive	53	SIM12 PR24-48 RGT	Median 48.0 (range 27 to 67)	91	NA	NA	NA	NA	0	0	0	100	79	19	0	0	0	0	0	0	G1d (1.9)	5.70	94.3	6.57 (4.9 to 7.4)	
	Exp	15	SIM12 PR24-48 RGT	Median 49.0 (range 34 to 67)	67	100	NA	NA	NA	100	0	0	100	80	20	0	0	0	0	0	0	0	0	6.7	93.3	6.45 (5.4 to 7.2)
	Exp	10	SIM12 PR48	Median 48.0 (range 43 to 57)	90	100	NA	NA	NA	0	0	100	100	90	10	0	0	0	0	0	0	0	0	10	90	6.22 (5.7 to 7.1)
	Exp	28	(SIM12 PR48	Median 47.0 (range 31 to 58)	82	100	NA	NA	NA	0	100	0	100	86	14	0	0	0	0	0	0	0	0	28.6	71.4	6.49 (5.3 to 7.5)
Gane et al., 2013-1 ELECTRON	Naive	10	SOF12 + RBV12	Mean 47 (range 36 to 53)	80	NA	NA	NA	NA	NA	NA	NA	0	0	0	40	60	0	0	0	0	0	NA	100	Median 6.7 (range 5.7 to 7.1)	
		11	SOF12 + PR12	Mean 46 (range 37 to 57)	82	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	36	64	0	0	0	0	0	NA	100	Median 6.5 (range 5.1 to 7.3)
Gane et al., 2013-2 ELECTRON	Exp	10	SOF12 + RBV12	Mean 48 (range 30 to 58)	70	NR	NR	0	<sup>a</sup>	0	100	0	100	90	10	0	0	0	0	0	0	0	NA	100	Median 7.0 (range 5.6 to 7.5)	
Gane et al., 2013-3 ELECTRON	Naive	25	SOF12 + RBV12	Mean 49 (range 22 to 69)	60	NA	NA	NA	NA	NA	NA	NA	100	88	12	0	0	0	0	0	0	0	NA	100	Median 6.2 (range 4.4 to 7.2)	

INCLUDED STUDIES	POPULATION	ITT, N	TREATMENT ARM	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	PREVIOUS TREATMENT EXPERIENCE				PREVIOUS RESPONSE			GENOTYPE AND SUBTYPE (%)										PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)
						PR (%)	DAA + PR (%)	DAA ONLY (%)	MIXED	RELAPSE (%)	NULL (%)	PARTIAL (%)	1	1a	1b	2	3	4	5	6	COMBINED/ OTHER	CIRRHOTIC (%)	NON-CIRRHOTIC (%)		
Gane et al., 2014-1 ELECTRON	Naive	25	SOF12 + LDV12 + RBV12	Mean 45 (SD 9.2)	32	NA	NA	NA	NA	NA	NA	NA	100	80	20	0	0	0	0	0	0	0	NA	100	Mean 5.9 (SD 0.9)
Gane et al., 2014-2 ELECTRON	Exp	9	SOF12 + LDV12 + RBV12	Mean 50 (SD 13)	78	NR	NR	0	<sup>a</sup>	0	100	0	100	89	11	0	0	0	0	0	0	0	NA	100	Mean 6.9 (SD 0.2)
Gane et al., 2014-3 ELECTRON	Exp	9	SOF12 + LDV12 + RBV12	Mean 57 (SD 5.2)	89	NR	NR	0	<sup>a</sup>	0	100	0	100	78	22	0	0	0	0	0	0	0	NA	0	Mean 6.3 (SD 0.8)
Jacobson et al., 2013 Fusion	Exp	103	SOF12 + RBV12	Mean 54 (range 30 to 69)	71	NR	NA	NA	<sup>a</sup>	76	24	3	NR	NR	35	62	0	0	0	0	0	35	65	6.5 (SD 0.67)	
KuMada et al., 2014	Naive	135	DCV24 + ASU24	NR (NR)/64.0 (24 to 75)	28	0	0	0		0	0	0			100								8.1	91.9	6.6 (0.58)
	Exp	87	DCV24 + ASU24	NR (NR)/60.0 (42 to 74)	45	100	0	0		0	55.2	41.4			100									12.6	87.4
Lalezari et al., 2015	Combined	38	PAR/RIT12 + OMB12 + DAS12 + RBV12	48.2 (11.0)	66	5.3	NA	NA	0	NR	NR	NR	100	84	NR	0	0	0	0	0	0	0	0	100	6.58 (0.70)

INCLUDED STUDIES	POPULATION	ITT, N	TREATMENT ARM	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	PREVIOUS TREATMENT EXPERIENCE				PREVIOUS RESPONSE			GENOTYPE AND SUBTYPE (%)										PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)
						PR (%)	DAA + PR (%)	DAA ONLY (%)	MIXED	RELAPSE (%)	NULL (%)	PARTIAL (%)	1	1a	1b	2	3	4	5	6	COMBINED/ OTHER	CIRRHOTIC (%)	NON-CIRRHOTIC (%)		
Lawitz et al., 2014 COSMOS	Exp	27	SOF12+ SI M12+ RBV 12	NR (NR)/55 (28 to 67)	74	100	0	0		0	100	0		78	22							0	100	6.7 (0.44)	
		14	SIM12 + SOF12	NR (NR)/56 (35 to 68)	58	100	0	0		0	100	0		71	29							0	100	6.7 (0.32)	
	Combined	27	SOF12+ SI M12+ RBV 12	NR (NR)/57 (36 to 68)	74	56	0	0		0	56	0		81	19							41	59	6.6 (0.52)	
		14	SIM12 + SOF12	NR (NR)/58 (47 to 64)	71	50	0	0		0	50	0		79	21							50	50	6.7 (0.48)	
Lawitz et al., 2014 LONE-STAR	Naive	20	SOF8 + LDV8	48 (10.7)/NR (NR)	70	0	0	0		0	0	0		85	15							0	100	6.1 (0.8)	
		21	SOF8 + LDV8 + RBV8	50 (11.1)/NR (NR)	57	0	0	0		0	0	0		90	10							0	100	6 (0.8)	
		19	SOF12 + LDV12	46 (11.6)/NR (NR)	58	0	0	0		0	0	0		89	11							0	100	6.1 (0.8)	
	Exp	19	SOF12 + LDV12	54 (6.6)/NR (NR)	79	0	100	0		37	63	0		95	5							58	42	6.3 (0.5)	
		21	SOF12 + LDV12 + RBV12	52 (9.8)/NR (NR)	67	0	100	0		29	71			76	24							52	48	6.2 (0.4)	
Manns et al., 2014 HALLMAR K-DUAL	Naive	205	DCV24 + ASU24	NR (NR)/55 (20 to 79)	49	NA	NA	NA		NA	NA	NA			100							16	84	NR	
	Exp	205	DCV24 + ASU24	NR (NR)/58 (23 to 77)	54	100	0	0		1	58	41			100							31	69	NR	

INCLUDED STUDIES	POPULATION	ITT, N	TREATMENT ARM	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	PREVIOUS TREATMENT EXPERIENCE				PREVIOUS RESPONSE			GENOTYPE AND SUBTYPE (%)										PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)	
						PR (%)	DAA + PR (%)	DAA ONLY (%)	MIXED	RELAPSE (%)	NULL (%)	PARTIAL (%)	1	1a	1b	2	3	4	5	6	COMBINED/ OTHER	CIRRHOTIC (%)	NON-CIRRHOTIC (%)			
	Combined	235	DCV24 + ASU24	NR (NR)/60 (24 to 77)	42	NR	0	0	b	0	0	0			100									47	53	NR
Mizokami et al., 2015 NA	Naive	83	SOF12 + LDV12	60 (9.2)	40	NA	NA	NA	NA	NA	NA	NA	100	4	96	0	0	0	0	0	0	0	24	76	6.6 (0.5)	
	Exp	88				61	19	NR	NR	0.5	0.33															
	Naive	83	SOF12 + LDV12 + RBV12	59 (9.5)	43	NA	NA	NA	NA	NA	NA	NA	100	2	98	0	0	0	0	0	0	0	21	79		
	Exp	87				54	26	NR	NR	0.51	0.32															
Molina et al., 2015 PHOTON-2	Naive	112	SOF24 + RBV24	Median (range): 45 (18 to 64)	89	NA	NA	NA	NA	NA	NA	NA	100	89	10	0	0	0	0	0			15	85	6.3 (0.7)	
	Naive	19	SOF12 + RBV12	Median (range): 55 (41 to 73)	79	NA	NA	NA	NA	NA	NA	NA	0	0	0	100	0	0	0	0			5	95	6.7 (0.7)	
	Exp	6	SOF24 + RBV24	Median (range): 55 (37 to 67)	100	NR	NR	NR	NR	NR	NR	NR	0	0	0	100	0	0	0	0			33	67	Mean (SD): 6.4 (0.6)	
	Naive	57	SOF24 + RBV24	Median (range): 47 (28 to 57)	67	NA	NA	NA	NA	NA	NA	NA	0	0	0	0	100	0	0	0			5	95	Mean (SD): 6.3 (0.7)	

INCLUDED STUDIES	POPULATION	ITT, N	TREATMENT ARM	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	PREVIOUS TREATMENT EXPERIENCE				PREVIOUS RESPONSE			GENOTYPE AND SUBTYPE (%)										PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)
						PR (%)	DAA + PR (%)	DAA ONLY (%)	MIXED	RELAPSE (%)	NULL (%)	PARTIAL (%)	1	1a	1b	2	3	4	5	6	COMBINED/ OTHER	CIRRHOTIC (%)	NON-CIRRHOTIC (%)		
	Exp	49	SOF24 + RBV24	Median (range): 49 (30 to 66)	78	NR	NR	NR	NR	NR	NR	NR	0	0	0	0	100	0	0	0		47	53	Mean (SD): 6.3 (0.8)	
	Naive	31	SOF24 + RBV24	Median (range): 47 (28 to 55)	77	NA	NA	NA	NA	NA	NA	NA	0	0	0	0	0	100	0	0		26	74	Mean (SD): 5.9 (0.9)	
Muir et al., 2015 UNITY-2	Naive	55	DCV12 + ASU12 + BEC12 + RBV12	59 (35 to 73)	64	0	0	0	0	0	0	0	98	71	27	0	0	0	0	2	0	100	0	6.36 (0.84)	
		57	DCV12 + ASU12 + BEC12	58 (25 to 75)	68	0	0	0	0	0	0	0	0	100	70	30	0	0	0	0	0	0	100	0	6.48 (0.62)
	Exp	45	DCV12 + ASU12 + BEC12 + RBV12	60 (48 to 73)	60	NR	NR	NR	100	17.8	35.6	4.4	100	78	22	0	0	0	0	0	0	0	100	0	6.65 (0.49)
		45	DCV12 + ASU12 + BEC12	59 (19 to 76)	71	NR	NR	NR	100	17.8	42.2	13.3	100	78	22	0	0	0	0	0	0	0	100	0	6.75 (0.36)
Nelson D. et al., 2015 ALLY-3 (AI444-218)	Naive	101	DCV12 + SOF12	53 (range 24 to 67)	58	NA	NA	NA	NA	NA	NA	NA	0	0	0	0	100	0	0	0	0	19	81	NR	
	Exp	51	DCV12 + SOF12	58 (range 40 to 73)	63	NR	NR	NR	NR	61	14	4	0	0	0	0	100	0	0	0	0	0	25	75	NR
Omata et al., 2014	Naive	90	SOF12 + RBV12	55 (range 25 to 73)	37	NA	NA	NA	NA	NA	NA	NA	0	0	0	100	0	0	0	0	<sup>c</sup>	9	91	6.2 (0.92)	
	Exp	63	SOF12 + RBV12	60 (range 34 to 74)	59	NR	NR	NR	NR	71	NR	NR	0	0	0	100	0	0	0	0	<sup>d</sup>	14	86	6.5 (0.66)	

INCLUDED STUDIES	POPULATION	ITT, N	TREATMENT ARM	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	PREVIOUS TREATMENT EXPERIENCE				PREVIOUS RESPONSE			GENOTYPE AND SUBTYPE (%)										PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)
						PR (%)	DAA + PR (%)	DAA ONLY (%)	MIXED	RELAPSE (%)	NULL (%)	PARTIAL (%)	1	1a	1b	2	3	4	5	6	COMBINED/ OTHER	CIRRHOTIC (%)	NON-CIRRHOTIC (%)		
Pearlman et al., 2015	Naive	62	SIM12 + SOF12	59.9 (mean)	66	NA	NA	NA	NA	NA	NA	NA	100	100	NA	NA	NA	NA	NA	NA	NA	100	NA	6.22 (0.44)	
	Exp		SIM12 + SOF12			100	NA	NA	NA	NA	100	NA													
	Naive	31	SOF12 + PR12	55 (mean)	63	NA	NA	NA	NA	NA	NA	NA	100	100	NA	NA	NA	NA	NA	NA	NA	100	NA	6.41 (0.59)	
	Exp		SOF12 + PR12			100	NA	NA	NA	NA	100	NA													
Poordad et al. et al., 2015 UNITY-1	Naive	312	DCV12 + ASU12 + BEC12	53.5 (range 19 to 77)	56	0	0	0	0	0	0	0	100	73	27	0	0	0	0	0	0	0	NA	100.0	21.8% < 800,000 IU/mL
	Exp	103	DCV12 + ASU12 + BEC12	57.0 (range 22 to 69)	62	NR	NR	NR	100	37.9	24.3	11.7	100	73	27	0	0	0	0	0	0	0	NA	100.0	9.7% < 800,000 IU/mL
Ruane et al., 2014	Naive	31	SOF12 + RBV12	53 (mean) (26 to 72)	71	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	100	NA	NA	NA	23	77.419	6.0 (4.7 to 7.0)	
	Exp		SOF12 + RBV12			100	0	0	12	29	59	NR													
	Naive	29	SOF24 + RBV24	55 (mean) (27 to 75)	66	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	100	NA	NA	NA	24	75.86	6.0 (4.3 to 7.2)	

INCLUDED STUDIES	POPULATION	ITT, N	TREATMENT ARM	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	PREVIOUS TREATMENT EXPERIENCE				PREVIOUS RESPONSE			GENOTYPE AND SUBTYPE (%)										PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)	
						PR (%)	DAA + PR (%)	DAA ONLY (%)	MIXED	RELAPSE (%)	NULL (%)	PARTIAL (%)	1	1a	1b	2	3	4	5	6	COMBINED/ OTHER	CIRRHOTIC (%)	NON-CIRRHOTIC (%)			
	Exp		SOF24 + RBV24			100	0	0	26	7	67	NR														
Sulkowski et al., 2014	Naive	68	SOF12 + RBV12	49 (mean) (24 to 71)	80.9	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	38.2	61.8	NA	NA	NA	NA	NA	10.3	89.7	6.3 ± 0.60	
	Naive	114	SOF24 + RBV24	48 (mean) (25 to 70)	81.6	NA	NA	NA	NA	NA	NA	NA	100	78.9	21.1	NA	NA	NA	NA	NA	NA	NA	4.4	95.6	6.6 ± 0.83	
	Exp	41	SOF24 + RBV24	54 (mean) (34 to 68)	90.2	100	NA	NA	NA	NR	NR	NR	NA	NA	NA	58.5	41.5	NA	NA	NA	NA	NA	24.4	75.6	6.5 ± 0.69	
Sulkowski et al., 2014	Naive	41	DCV12 + SOF12	55 (NR)	49	NA	NA	NA	NA	NA	NA	NA	100	83	17	0	0	0	0	0	0	NA	NA	100	6.2 (0.5)	
Zeuzem et al., 2014	Naive	32	SOF12 + RBV12	58 (mean) (28 to 74)	55	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	100	NA	NA	NA	NA	NA	NA	15.0	84.9	6.5 ± 0.7	
	Exp	41				NA	NA	NA	100	38	14	4														
	Naive	105	SOF24 + RBV24	48 (mean) (19 to 69)	62	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	100	NA	NA	NA	NA	NA	24.0	76.0	6.3 ± 0.7	
	Exp	145				NA	NA	NA	100	38	16	4														

INCLUDED STUDIES	POPULATION	ITT, N	TREATMENT ARM	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	PREVIOUS TREATMENT EXPERIENCE				PREVIOUS RESPONSE			GENOTYPE AND SUBTYPE (%)										PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)
						PR (%)	DAA + PR (%)	DAA ONLY (%)	MIXED	RELAPSE (%)	NULL (%)	PARTIAL (%)	1	1a	1b	2	3	4	5	6	COMBINED/ OTHER	CIRRHOTIC (%)	NON-CIRRHOTIC (%)		
<b>Not Included in the NMA for all SVR</b>																									
Jacobson et al., 2013 POSITRON	Combined	207	SOF12 + RBV12	Mean 52 (range 21 to 75)	57	NA	NA	NA	NR	5	1	0	0	0	53	47	0	0	0	0	0	15	85	6.3 (SD 0.77)	
Lawitz et al., 2015-1 C-WORTHY	Naive	29	GRZ12 + ELB12 (50 mg q.d.)	59.0 (7.8)	66	0	0	0	NA	NA	NA	NA	100	69	24	NA	NA	NA	NA	NA	7	100	0	6.43 (0.61)	
		31	GRZ18 + ELB18 (50 mg q.d.)	58.9 (8.0)	68	0	0	0	NA	NA	NA	NA	NA	100	74	26	NA	NA	NA	NA	NA	NA	97	3	6.60 (0.53)
		31	GRZ12 + ELB12 (50 mg q.d.) + RBV12	57.0 (7.0)	61	0	0	0	NA	NA	NA	NA	NA	100	65	32	NA	NA	NA	NA	NA	3	100	0	6.53 (0.61)
		32	GRZ18 + ELB18 (50 mg q.d.) + RBV18	58.8 (8.2)	47	0	0	0	NA	NA	NA	NA	NA	100	75	25	NA	NA	NA	NA	NA	NA	100	0	6.40 (0.53)
Lawitz et al., 2015-2 C-WORTHY	Exp	33	GRZ12 + ELB12 (50 mg q.d.)	54.4 (9.1)	61	100	0	0	NA	NA	100	NA	100	67	33	NA	NA	NA	NA	NA	NA	42	58	6.67 (0.42)	
		32	GRZ12 + ELB12 (50 mg q.d.) + RBV12	52.2 (8.8)	63	100	0	0	NA	NA	100	NA	100	56	44	NA	NA	NA	NA	NA	NA	34	66	6.64 (0.57)	
		32	GRZ18 + ELB18	54.3 (12.3)	56	100	0	0	NA	NA	100	NA	100	53	47	NA	NA	NA	NA	NA	NA	34	66	6.8 (0.38)	



INCLUDED STUDIES	POPULATION	ITT, N	TREATMENT ARM	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	PREVIOUS TREATMENT EXPERIENCE				PREVIOUS RESPONSE			GENOTYPE AND SUBTYPE (%)										PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)		
						PR (%)	DAA + PR (%)	DAA ONLY (%)	MIXED	RELAPSE (%)	NULL (%)	PARTIAL (%)	1	1a	1b	2	3	4	5	6	COMBINED/ OTHER	CIRRHOTIC (%)	NON-CIRRHOTIC (%)				
			(50 mg q.d.)																								
		33	GRZ18 + ELB18 (50 mg q.d.) + RBV18	56.2 (10.9)	48	100	0	0	NA	NA	100	NA	100	58	42	NA	NA	NA	NA	NA	NA	NA	36	64	6.81 (0.44)		
Poordad et al., 2014 TUR-QUOISE-II	Naive	86	PAR/RIT12 + OMB12 + DAS12 + RBV12	57.1 (7.0)	70.2	NA	NA	NA	NA	NA	NA	NA	100	67	33	NA	NA	NA	NA	NA	NA	100	NA	6.41 (0.62)			
	Exp	122				100	NA	NA	NA	23.8	61.5	14.8															
	Naive	74	PAR/RIT24 + OMB24 + DAS24 + RBV24	56.5 (7.9)	70.3	NA	NA	NA	NA	NA	NA	NA	100	70.3	29.7	NA	NA	NA	NA	NA	NA	100	NA	6.53 (0.52)			
	Exp	98				100	NA	NA	NA	23.5	63.3	13.3															
Sulkowski et al., 2015-1 C-WORTHY	Naive	85	GRZ12 + ELB12 + RBV12	51.0 (20 to 70)	47	0	0	0	NA	NA	NA	NA	100	61	37	NA	NA	NA	NA	NA	NA	2	NA	100	6.21 (0.80)		
		44	GRZ12 + ELB12 (50 mg q.d.)	52.0 (24 to 73)	52	0	0	0	NA	NA	NA	NA	NA	100	68	32	NA	NA	NA	NA	NA	NA	NA	100	6.39 (0.56)		
		30	GRZ8 + ELB8 (50 mg q.d.) + RBV8	52.0 (25 to 63)	60	0	0	0	NA	NA	NA	NA	NA	100	100	NA	NA	NA	NA	NA	NA	NA	NA	100	6.38 (0.73)		

INCLUDED STUDIES	POPULATION	ITT, N	TREATMENT ARM	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	PREVIOUS TREATMENT EXPERIENCE				PREVIOUS RESPONSE			GENOTYPE AND SUBTYPE (%)										PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)
						PR (%)	DAA + PR (%)	DAA ONLY (%)	MIXED	RELAPSE (%)	NULL (%)	PARTIAL (%)	1	1a	1b	2	3	4	5	6	COMBINED/ OTHER	CIRRHOTIC (%)	NON-CIRRHOTIC (%)		
Sulkowski et al., 2015-2 C-WORTHY	Naive	30	GRZ12 + ELB12 (50 mg q.d.)	44.5 (22 to 62)	80	0	0	0	NA	NA	NA	NA	100	73	27	NA	NA	NA	NA	NA	NA	NA	NA	100	6.36 (0.99)
		29	GRZ12 + ELB12 (50 mg q.d.) + RBV12	48.0 (27 to 63)	79	0	0	0	NA	NA	NA	NA	NA	100	83	17	NA	NA	NA	NA	NA	NA	NA	NA	100
Sulkowski et al., 2015 TURQUOI SE-I-1a	Naive	20	PAR/RIT12 + OMB12 + DAS12 + RBV12	50.9 (6.0)	0.94	0	0	0	NA	0	0	0	100	87	13	NA	NA	NA	NA	NA	NA	19	81	6.54 (0.57)	
	Exp	11	PAR/RIT12 + OMB12 + DAS12 + RBV12			100	0	0	NR	9	45	45													

ASU = asunaprevir; BEC = beclabuvir; DAA = direct-acting antiviral; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; exp = experienced; GRZ = grazoprevir; ITT = intention-to-treat; IU = international unit; LDV = ledipasvir; NA = not applicable; NMA = network meta-analysis; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q.d. = once daily; RBV = ribavirin; RGT = response-guided therapy; RIT = ritonavir; SD = standard deviation; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.

<sup>a</sup> Previous treatment with ≥ 12 weeks PR required to enter the study.

<sup>b</sup> Patients may or may not have been previously treated with PR.

<sup>c</sup> They further divided into G2a = 58, and G2b = 42.

<sup>d</sup> They further divided into G2a = 63, and G2b = 37.